Valuation: ACADIA Pharmaceuticals Inc.

Market Cap 4.45B 3.89B 3.57B 3.33B 6.32B 423B 6.41B 42.89B 16.67B 208B 16.69B 16.33B 717B P/E 2026 *
67.5x
P/E 2027 * 35.5x
Enterprise Value 3.48B 3.04B 2.8B 2.61B 4.95B 332B 5.02B 33.59B 13.06B 163B 13.07B 12.79B 562B EV / Sales 2026 *
2.81x
EV / Sales 2027 * 2.35x
Free-Float
99.68%
Yield 2026 *
-
Yield 2027 * -
1 day+3.06%
1 week+2.57%
Current month+2.65%
1 month+19.57%
3 months+16.98%
6 months-1.22%
Current year-2.77%
1 week 24.94
Extreme 24.935
26.23
1 month 20.84
Extreme 20.84
27.31
Current year 19.89
Extreme 19.89
27.81
1 year 19.69
Extreme 19.69
28.35
3 years 13.4
Extreme 13.4
33.99
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 20/09/2024
Director of Finance/CFO 52 10/09/2021
Chief Tech/Sci/R&D Officer - 04/08/2025
Director TitleAgeSince
Director/Board Member 68 01/05/2008
Chairman 55 10/06/2016
Director/Board Member 73 25/11/2015
Date Insider Type Main position Quantity % Market Cap.
06-26Sell

Controller/Auditor

-11,421 0.0067%
05-29
Baker Bros. Advisors LP
FreeCompany 101,260 0.0591%
05-29Fiscal year

Director

41,529 0.0243%
Change 5-day change 1-year change 3-year change Capi.($)
+3.06%+2.57%+23.96%+8.21% 4.45B
+1.70%+7.41%+2.50%+8.22% 49.92B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+8.30%+40.44% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+14.00%+19.59% 13.86B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +2.26%+6.19%+73.27%+108.05% 25.01B
Weighted average by Cap. +2.08%+6.59%+88.94%+135.43%

Financials

2026 *2027 *
Net sales 1.24B 1.09B 997M 929M 1.76B 118B 1.79B 11.97B 4.65B 58.09B 4.66B 4.56B 200B 1.39B 1.22B 1.12B 1.04B 1.98B 133B 2.01B 13.45B 5.23B 65.26B 5.23B 5.12B 225B
Net income 66M 57.69M 53.02M 49.42M 93.74M 6.28B 95.16M 637M 247M 3.09B 248M 242M 10.64B 133M 116M 107M 99.65M 189M 12.67B 192M 1.28B 499M 6.23B 499M 489M 21.46B
Net Debt -965M -843M -775M -722M -1.37B -91.84B -1.39B -9.3B -3.62B -45.14B -3.62B -3.54B -156B -1.18B -1.03B -946M -881M -1.67B -112B -1.7B -11.35B -4.41B -55.09B -4.42B -4.32B -190B
Logo ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
02/07/26 $25.97 +3.06% 1,586,395
01/07/26 $25.20 -0.40% 1,417,658
30/06/26 $25.30 +0.40% 1,721,284
29/06/26 $25.20 -0.47% 2,090,012
26/06/26 $25.32 +6.75% 7,370,513
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
25.97USD
Average target price
32.30USD
Spread / Average Target
+24.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACAD Stock